Monocyte tumor necrosis factor receptor levels as a predictor of risk in human sepsis

Archives of Surgery

Volumn 131, Issue 4, 1996, Pages 434-437

  Calvano, Steve E ^a   Van Der Poll, Tom ^a   Coyle, Susette M ^a   Barie, Philip S ^a   Moldawer, Lyle L ^a,b   Lowry, Stephen F ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC VALUE; HUMAN; INFECTION RISK; MONOCYTE; PRIORITY JOURNAL; RISK ASSESSMENT; SEPSIS;

EID: 0029946033     PISSN: 00040010     EISSN: None     Source Type: Journal    
DOI: 10.1001/archsurg.1996.01430160092020     Document Type: Article

References (28)

1. Centers for Disease Control. Increase in national hospital discharge survey rates for septicemia - United States. 1979-1987. MMWR CDC Surveill Summ. 1990; 39:31-34.
2. Wenzel RP. Anti-endotoxin monclonal antibodies N Engl J Med. 1992;326: 1151-1152.
3. Bone RC The pathogenesis of sepsis Ann Intern Med. 1991;115 457-469.
4. Rackow EC, Astiz ME The pathophysiology and treatment of septic shock. JAMA 1991,266:548-554.
5. Ziegler EJ, Fisher CJ, Sprung CI, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. N Engl J Med 1991;324:429-436
6. Greenman RL, Schein RMH, Martin MA, et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 1991;265:1097-1102.
7. Van Zee KJ, Coyle SM, Calvano SE, et al. Influence of IL-1 receptor blockade on the human response to endotoxemia J Immunol 1995;154:1499-1507
8. Marra MN, Thorton MB, Snable JL, Wilde CG, Scott RW. Endotoxin-binding and -neutralizing properties of recombinant bactericidal/permeability-increasing protein and monoclonal antibodies HA-1A and E5. Crit Care Med. 1994,22:559-565.
9. Lowry SF, Calvano SE. Soluble cytokine and hormonal mediators of immunity and inflammation. In: Howard RJ, Simmons RJ, eds. Surgical infectious Diseases, 3rd ed. Norwalk, Conn: Appleton & Lange; 1995:313-326.
10. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive TNF-alpha in vitro and in vivo. Proc Natl Acad Sci U S A. 1992;89:4845-4849
11. Marano MA, Fong Y, Moldawer LL, et al. Serum cachectin/TNF in critically ill burn patients correlates with infection and mortality. Surg Gynecol Obstet. 1990; 170:32-38.
12. Barriere SL, Lowry SF An overview of mortality risk prediction in sepsis. Crit Care Med. 1995;23:376-393
13. Cannon JG, Tompkins RG, Gelfand JA, et al. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 1990;161:79-84.
14. Meek M, Munster AM, Winchurch RA, Dickerson C. The Baltimore Sepsis Scale: measurement of sepsis in patients with burns using a new scoring system. J Burn Care Rehabil. 1991;12:564-568.
15. Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med. 1993,119: 771-778
16. Van der Poll T, Jansen J, van Leenen D, et al Release of soluble receptors for tumor necrosis factor in clinical sepsis and experimental endotoxemia. J Infect Dis. 1993;168.955-960.
17. Ertel W, Scholl FA, Gallati H, Bonaccio M, Schildberg F-W, Trentz O. Increased release of soluble tumor necrosis factor receptors into blood during clinical sepsis. Arch Surg. 1994;129:1330-1337.
18. Rogy MA Coyle SM, Rock CS, et al. Persistently elevated soluble tumor necrosis factor receptor and interleukin-1 receptor antagonist levels in critically ill patients. J Am Coll Surg 1994,178:132-138.
19. Porteu F, Nathan C Shedding of tumor necrosis factor receptors by activated human neutrophils. J Exp Med. 1990,172:599-607.
20. Leeuwenberg JFM, Dentener MA, Buurman WA. Lipopolysaccharide LPS-mediated soluble TNF receptor release and TNF receptor expression by monocytes: role of CD14, LPS binding protein, and bacteridical/permeability-increasing protein. J Immunol. 1994;152:5070-5076.
21. Ferrante A, Martin AJ, Bates EJ, et al. Interaction of Staphylococcus aureus with human neutrophils and the down-regulation of TNF receptors. J Immunol 1994;152 3998-4004.
22. Leeuwenberg JFM, Jeunhommee TMAA, Buurman WA Slow release of soluble TNF receptors by monocytes in vitro. J Immunol 1994,152:4036-4043
23. Rogy MA, Oldenburn HSA, Calvano SE, et al The role of bactericidal/permeability-increasing protein in the treatment of primate bacteremia and septic shock. J Clin Immunol. 1994;14:120-133.
24. Van der Poll T, Calvano SE, Kumar A, et al Endotoxin induces downregulation of tumor necrosis factor receptors on circulating monocytes and granulocytes in humans. Blood 1995;86.2754-2759
25. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz GA. Balk RA Sepsis syndrome a valid clinical entity Crit Care Med. 1989;17:389-393.
26. Ding AH, Sanchez E, Srimal S, Nathan CF. Macrophages rapidly internalize their tumor necrosis factor receptors in response to bacterial lipopolysaccharide. J Biol Chem. 1989;264 3924-3929
27. Imamura K, Spriggs D, Kufe D Expression of tumor necrosis factor receptors on human monocytes and internalization of receptor bound ligand. J Immunol 1987;139 2989-2992
28. Winzen R, Wallach D, Engelmann H, et al. Selective decrease in cell surface expression and mRNA level of the 55-kda tumor necrosis factor receptor during differentiation of HL-60 cells in macrophage-like but not granulocyte-like cells J Immunol. 1992;148:3454-3460.